Submissions from 2018
Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis, Minesh Mehta
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539, Minesh Mehta
Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation, Minesh Mehta
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02, Minesh Mehta
Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms, Minesh Mehta
Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations, Minesh Mehta
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists, Minesh Mehta
Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus, Minesh Mehta
What is the evidence for the clinical value of SBRT in cancer of the cervix?, Minesh Mehta
Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?, Minesh Mehta and Rupesh Kotecha
Dosimetric Impact of Large Displacement of the Metal Port of the Tissue Expander in Intensity Modulated Proton Therapy, Jen Yu, Jaafar Bennouna, and Minesh Mehta
Submissions from 2017
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee, Michael Chuong
The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings, Michael Chuong
A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients, Michael Chuong and Minesh Mehta
Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer, Minesh Mehta
Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials, Minesh Mehta
Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer, Minesh Mehta
Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation, Minesh Mehta
State of the art: the evolving role of RT in combined modality therapy for GBM, Minesh Mehta
The Changing Role of Whole-Brain Radiotherapy: Demise or Time for Selective Usage?, Minesh Mehta
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases, Minesh Mehta
The role of radiation in treating glioblastoma: here to stay, Minesh Mehta
Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer, Minesh Mehta and Michael Chuong
Radiation Therapy for Liver Tumors: The State-of-the-art, Miguel Perez and Michael Chuong
Submissions from 2016
HPV-Associated Oropharyngeal Cancer: Changing Treatment Paradigm & Prognosis, Andre Abitbol
An overview of modern proton therapy, Minesh Mehta
Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer, Minesh Mehta
Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review, Minesh Mehta
Clinical ramifications of "genomic staging" of low-grade gliomas, Minesh Mehta
International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties, Minesh Mehta
Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study, Minesh Mehta
Reply to M.C. Chamberlain, Minesh Mehta
Stereotactic Radiosurgery for Treatment of Brain Metastases, Minesh Mehta
Submissions from 2014
Predictors of radiotherapy-related GI toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529, Andre Abitbol
Submissions from 2012
Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer, Alan Lewin, Robert Derhagopian, Andre Abitbol, D Jay Wieczorek, Vivek Mishra, and Lourdes Moreno
Submissions from 2007
Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife, William Brown, Alan Lewin, and Andre Abitbol
Submissions from 2005
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol, Andre Abitbol, Alan Lewin, and Michael Troner
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma, Andre Abitbol, Alan Lewin, and Michael Troner
Submissions from 2002
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol, Andre Abitbol, Alan Lewin, Michael Troner, and Maria-Amelia Rodrigues
Submissions from 1996
Management of stage I-B, II-A, and II-B carcinoma of the cervix with high-dose-rate brachytherapy: initial results of an institutional clinical trial, Andre Abitbol and Alan Lewin
Submissions from 1993
Submissions from 1992
Stereotactic radiosurgery: dose-volume analysis of linear accelerator techniques, Christopher Serago, Alan Lewin, Andre Abitbol, Sergio Gonzalez-Arias, and Victor Marcial-Vega
Submissions from 1991
Scattering effects on the dosimetry of iridium-192, Christopher Serago, Andre Abitbol, Alan Lewin, and Victor Marcial-Vega
Stereotactic target point verification of an X ray and CT localizer, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, and Andre Abitbol
Improved linac dose distributions for radiosurgery with elliptically shaped fields, Christopher Serago, Alan Lewin, Sergio Gonzalez-Arias, Andre Abitbol, and Victor Marcial-Vega